Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine + Daratumumab + Dexamethasone in RRMM
NCT04407442Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Nov 2020
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in multiple myeloma (MM), sponsored by University of California, San Francisco. Started Nov 2020; status: terminated.
02
Drugs
azacitidine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04407442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04407442.